ATG 008
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for ATG 008, covering 2021-05-17 to 2021-08-10. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Evaluate Dual mTORC1/2 Inhibitor (ATG 008) or Selective Inhibitor of Nuclear Export Compound (ATG-010) in Combination With Chemotherapy in Patients With Relapsed or Metastatic Ovarian Cancer, Endometrial Cancer, and Cervical Cancer ( PORCH ) [Phase 2]